Supernus Pharmaceuticals Inc expected to post a loss of 23 cents a share - Earnings Preview

Supernus Pharmaceuticals

05/08/2023 03:08

* Supernus Pharmaceuticals Inc  SUPN.OQ   SUPN.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 8. 
    * The Rockville Maryland-based  company is expected to
report  a
15.5% decrease in revenue to $143.658 million from $170.05
million a year ago, according to the mean estimate from 4
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Supernus
Pharmaceuticals
Inc is for a loss of 23 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Supernus
Pharmaceuticals Inc is $43​, above​ its last closing price
of $32.18. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  0.13        0.17       0.29      Beat    70.6
 Dec. 31 2023  0.70        0.68       0.43      Missed  -36.8
 Sep. 30 2022  0.44        0.36       0.03      Missed  -91.6​
 Jun. 30 2022  0.33        0.29       0.14      Missed  -51.7
 ​​Mar.        0.25        0.24       0.43      Beat    79.2
 31 2022                                                
 Dec. 31 2021  0.29        0.24       0.04      Missed  -83.1​
 Sep. 30 2021  0.23        0.23       0.40      Beat    72
 Jun. 30 2021  0.20        0.20       0.43      Beat    117.7
 This summary was machine generated August 5 at 02:07 GMT.  All
figures in US dollars  unless otherwise stated